Drug Trial Radar · NCT07095452
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
680
Planned (sponsor's estimate)
Start
Jan 8, 2026
Primary completion
Mar 2041
Study completion Jan 2042
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- IFM (Intergroupe Français du Myélome); PETHEMA (Program for the Study and Treatment of Haematological Malignances)
- First posted
- Jul 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change in disease activity, and pharmacokinetics of Etentamig in adult participants with MM. Etentamig is an investigational drug being developed for the treatment of MM. This study is broken into 2 phases; a phase 2 dose selection and optimization cohort with 3 study arms and a subcutaneous (SC) safety cohort with 2 study arms. Phase 3 participants will receive etentamig at recommended Phase 3 dose (RP3D). Around 680 adult participants with MM will be enrolled at approximately 155 sites worldwide Participants in the phase 2 dose selection and optimization cohort will receive 1 of 3 doses of etentamig as intravenous (IV) infusions, combination with subcutaneous (SC) injections of daratumumab. The Phase 2 subcutaneous (SC) safety cohort participants will receive 1 of 2 doses of etentamig in combination with daratumumab. Participants in phase 3 will receive RP3D doses of etentamig as IV infusions, combination with SC injections of daratumumab, or SC injections of daratumumab, capsules of lenalidomide, and tablet/ IV injections of dexamethasone (DRd). The study duration is approximately 16 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Conditions
- Multiple Myeloma
Interventions
EtentamigDrug
Intravenous (IV) Infusion
LenalidomideDrug
Oral Capsule
DaratumumabDrug
Subcutaneous Injection
DexamethasoneDrug
Oral Tablet
DexamethasoneDrug
IV Injection
EtentamigDrug
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2 and 3: Percentage of Participants with Adverse Events (AE)sTime frame: Up to Approximately 16 Years
- Phase 2: Change in Clinical ActivityTime frame: Up to Approximately 52 weeks
- Phase 3: Minimal Residual Disease (MRD) Negative CR RateTime frame: Up to Approximately 52 weeks
- Phase 3: Progression-Free Survival (PFS)Time frame: Up to Approximately 130 Months
Locations
49 sites in 4 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital Scottsdale /ID# 278349
Scottsdale, Arizona · Recruiting
Cedars-Sinai Medical Center /ID# 278238
Los Angeles, California · Recruiting
Colorado Blood Cancer Institute /ID# 279080
Denver, Colorado · Recruiting
Winship Cancer Institute of Emory University /ID# 277667
Atlanta, Georgia · Recruiting
Fort Wayne Medical Oncology And Hematology /ID# 278141
Fort Wayne, Indiana · Recruiting
Minnesota Oncology - Minneapolis Clinic /ID# 278720
Minneapolis, Minnesota · Recruiting
Mayo Clinic Hospital Rochester /ID# 277886
Rochester, Minnesota · Recruiting
Icahn School of Medicine at Mount Sinai /ID# 277844
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946
New York, New York · Recruiting
Weill Cornell Medicine Myeloma Center /ID# 278216
New York, New York · Recruiting
University of North Carolina at Chapel Hill /ID# 277708
Chapel Hill, North Carolina · Recruiting
Willamette Valley Cancer Institute and Research Center /ID# 278721
Eugene, Oregon · Recruiting
SCRI Oncology Partners /ID# 278353
Nashville, Tennessee · Recruiting
Texas Oncology - The Woodlands /ID# 278726
The Woodlands, Texas · Recruiting
Texas Oncology - Northeast Texas /ID# 278725
Tyler, Texas · Recruiting
Virginia Cancer Specialists - Fairfax /ID# 278716
Fairfax, Virginia · Recruiting
Blue Ridge Cancer Care - Roanoke /ID# 278722
Roanoke, Virginia · Recruiting
Hopital Saint-Louis /ID# 278429
Paris, France · Recruiting
Hopital Saint Antoine /ID# 278428
Paris, France · Recruiting
Centre Hospitalier Annecy Genevois /ID# 278406
Epagny Metz Tessy, Auvergne-Rhône-Alpes, France · Recruiting
Centre Hospitalier De Dunkerque-Hospital Alexandra Lepeve /ID# 278399
Dunkirk, Hauts-de-France, France · Recruiting
Chu De Lille - Hopital Claude Huriez /ID# 278413
Lille, Hauts-de-France, France · Recruiting
CHU de Montpellier - Hopital Saint Eloi /ID# 278415
Montpellier, Herault, France · Recruiting
Hopital Universitaire Necker Enfants Malades /ID# 278426
Paris, Île-de-France Region, France · Recruiting
CHRU Tours - Hopital Bretonneau /ID# 279274
Tours, Indre-et-Loire, France · Recruiting
CH Bretagne Atlantique /ID# 278422
Vannes, Morbihan, France · Recruiting
Centre Hospitalier Universitaire de Bordeaux /ID# 278419
Pessac, New Aquitaine, France · Recruiting
Centre Hospitalier Universitaire de Poitiers /ID# 278398
Poitiers, New Aquitaine, France · Recruiting
IUCT Oncopole /ID# 278403
Toulouse, Occitanie, France · Recruiting
Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 278402
Nantes, Pays de la Loire Region, France · Recruiting
Centre Hospitalier Universitaire de Saint Etienne - Hopital Nord /ID# 278421
St-Priest-en-Jarez, Pays de la Loire Region, France · Recruiting
HCL - Hopital Lyon Sud /ID# 282145
Pierre-Bénite, Rhone, France · Recruiting
Nagoya City University Hospital /ID# 278188
Nagoya, Aichi-ken, Japan · Recruiting
Matsuyama Red Cross Hospital /ID# 278660
Matsuyama, Ehime, Japan · Recruiting
Kurume University Hospital /ID# 278209
Kurume-shi, Fukuoka, Japan · Recruiting
Tokai University Hospital /ID# 278157
Isehara, Kanagawa, Japan · Recruiting
University Hospital Kyoto Prefectural University of Medicine /ID# 278156
Kyoto, Kyoto, Japan · Recruiting
Hospital Clinic de Barcelona /ID# 278532
Barcelona, Spain · Recruiting
Complejo Asistencial Universitario de Leon - Hospital de Leon /ID# 278534
León, Spain · Recruiting
Hospital General Universitario Gregorio Maranon /ID# 278551
Madrid, Spain · Recruiting
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.